ENTITY
Shanghai Haohai Biological Technology

Shanghai Haohai Biological Technology (6826 HK)

136
Analysis
Health Care • China
Shanghai Haohai Biological Technology engages in the research, development, manufacture, and sale of biomedical materials and pharmaceutical products. The company focuses on therapeutic areas including ophthalmology, medical aesthetics and wound care, orthopedics, and anti-adhesion and hemostasis, with key products such as intraocular lenses, hyaluronic acid dermal fillers, and sodium hyaluronate injections. It is headquartered in Shanghai, China, and was founded in 2007.
more
•12 Jul 2026 10:15

A-H Premium Weekly (Jul 10th): Hua Hong Semi, Smic, Yangtze Optical Fibre And-H, Innocare

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Hua Hong Semi, Smic, Yangtze Optical Fibre And-H, Innocare.

Logo
132 Views
Share
•05 Jul 2026 10:15

A-H Premium Weekly (Jul 3rd): China Longyuan, Psbc, Cicc, Yangtze Optical Fibre And-H, Midea

We analyzed A-H premium changes in the past week and highlight A-H premium changes for China Longyuan, Psbc, Cicc, Yangtze Optical Fibre And-H,...

Logo
127 Views
Share
•14 Jun 2026 10:15

A-H Premium Weekly (Jun 12th): Remegen, ZTE, Chalco, Shandong Gold Mining Co Lt-H

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Remegen, ZTE, Chalco, Shandong Gold Mining Co Lt-H.

Logo
101 Views
Share
•01 Jul 2019 13:55

Screening the Silk Road: Q3-2019 Small-Mid Cap GARP (Zulu Warrior Screening)

In January 2019, we re-examined the divide between value and growth stocks, citing expectation of a reversal to value based on historical data and...

Logo
684 Views
Share
•03 Jun 2026 16:46

Mindray (迈瑞医疗) A+H Pre-IPO: Early Thoughts

Mindray is seeking to raise at least USD500m through an A+H listing. The note covers business quality, industry context, peer valuation, and A-H...

Logo
156 Views
Share
x